📰 Antagonist Development Plan News
Antagonist Development Plan News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Antagonist Development Plan. Real-time updates on events, politics, business and more.
March 15, 2023
CTA-enabling work on track to seek approval to commence Phase 1 clinical trial of LMNL6511 during the second half of 2023 Addition of GPR40 agonist discovery...
March 15, 2023
CTA-enabling work on track to seek approval to commence Phase 1 clinical trial of LMNL6511 during the second half of 2023 Addition of GPR40 agonist discovery...
January 6, 2023
/PRNewswire/ -- Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), is pleased to provide an overview of the Companys priorities...
January 6, 2023
Closed December 2022 with just over CAD 37 million cash on hand, expecting to provide a runway into early 2024.Plans to divest its remaining non-core assets, to further extend runway.Nominated
January 6, 2023
/PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), is pleased to provide an overview of the Companys priorities...